Table 1 Patient characteristics at initiation of HAART stratified by gender (n = 908)

Subjects, n(%)

473 (52.1)

435 (47.9)

-

Follow-up from initiation of HAART (years), median (IQR)

5.9 (3.2-8.7)

5.7 (2.7-8.5)

-

Follow-up time from initiation of HAART, (person-years)

2833

2519

Age in years at HAART initiation, median (IQR)

33.0 (28.6-40.1)

43.2 (35.3-51.7)

<0.0001

Race, n(%)

 White

137 (29.0)

319 (73.7)

<0.0001

 Asian

76 (16.1)

12 (2.8)

 Black

250 (53.0)

90 (20.8)

 Other

9 (1.9)

12 (2.8)

 (missing)

(1)

(2)

Place of HIV transmission, n(%)

 Denmark

127 (28.5)

150 (38.3)

<0.0001

 Europe + US

19 (4.3)

29 (7.4)

 Africa

224 (50.3)

140 (35.7)

 Asia

72 (16.2)

63 (16.1)

 Other

3 (0.7)

10 (2.6)

 (missing)

(28)

(43)

CD4 cell count at HAART initiation (cells/μl), median (IQR)

All women included

196 (90–290)

180 (63–290)

0.12 (0.026)

Pregnant women excluded

170 (80–270)

180 (63–290)

0,87 (0,21)

HIV-RNA at HAART initiation (copies/mL), median (IQR) All women included

50,800 (12,500-204,000)

126,155 (32,200-501,000)

<0.0001 (0.0003)

Pregnant women excluded

61,320 (16,519-237,000)

126,155 (32,200-501,000)

<0.0001 (0.0066)

Acute HIV infection at HAART initiation, n(%)

4 (0.9)

15 (3.5)

0.0089

AIDS before HAART initiation, n(%) All women included

88 (18.6)

106 (24.4)

0.034

n(%) of all patients except pregnant women Pregnant women excluded

87 (21.8)

106 (24.4)

0.37

Pregnant at HAART initiation, n(%)

59 (12.5)

-

-

Antiretroviral therapy before HAART, n(%)

14 (3.0)

12 (2.8)

0.86

Hepatitis B co-infection², n(%)

30 (6.3)

20 (4.6)

0.25

Hepatitis C co-infection³, n(%)

0 (0)

-

-

First-line HAART 01.01.1997 – 31.12.2002 All women included

 3 NRTI’s⁴

21 (9.5)

9 (4.3)

0.29

 2 NRTI’s + efavirenz

71 (32.0)

76 (35.9)

 2 NRTI’s + nevirapine

7 (3.2)

6 (2.8)

 2 NRTI’s + PI’s⁵

93 (41.9)

94 (44.3)

 Other regimen

30 (13.5)

27 (12.7)

Pregnant women excluded

 3 NRTI’s

21 (11.1)

9 (4.7)

0.13

 2 NRTI’s + efavirenz

66 (37.7)

76 (39.8)

2 NRTI’s + nevirapine

5 (2.6)

6 (3.1)

 2 NRTI’s + PI’s

73 (38.4)

94 (44.3)

 Other regimen

25 (13.2)

27 (12.7)

First-line HAART 01.01.2003 – 31.12.2009 All women included

 3 NRTI’s

3 (1.2)

1 (0.5)

<0.0001

 2 NRTI’s + efavirenz

150 (59.8)

179 (80.3)

 2 NRTI’s + nevirapine

17 (6.8)

13 (5.8)

 2 NRTI’s + PI’s

73 (29.1)

20 (9.0)

 Other regimen

8 (3.2)

10 (4.5)

Pregnant women excluded

 3 NRTI’s

3 (1.4)

1 (0.5)

0.066

 2 NRTI’s + efavirenz

148 (70.5)

179 (80.3)

 2 NRTI’s + nevirapine

15 (7.1)

13 (5.8)

 2 NRTI’s + PI’s

36 (17.1)

20 (9.0)

 Other regimen

8 (3.8)

10 (4.5)